EFM
RARE icon

E Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

E Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Sell
14,334
-6,462
-31% -$161K 0.01% 278
2026
Q1 		$436K Buy
+20,796
New +$468K 0.01% 313
2025
Q2 		$329K Buy
9,052
+752
+9% +$27.1K 0.02% 286
2025
Q1 		$301K Buy
8,300
+1,100
+15% +$45.8K 0.01% 313
2024
Q4 		$303K Buy
7,200
+877
+14% +$43.5K 0.02% 313
2024
Q3 		$351K Sell
6,323
-1,339
-17% -$68.2K 0.02% 235
2024
Q2 		$315K Sell
7,662
-915
-11% -$39.1K 0.02% 224
2024
Q1 		$400K Sell
8,577
-3,294
-28% -$155K 0.02% 221
2023
Q4 		$568K Buy
11,871
+2,467
+26% +$95.6K 0.04% 134
2023
Q3 		$335K Buy
9,404
+711
+8% +$28.2K 0.03% 198
2023
Q2 		$401K Sell
8,693
-1,271
-13% -$59K 0.03% 166
2023
Q1 		$400K Sell
9,964
-434
-4% -$18.6K 0.03% 166
2022
Q4 		$482K Buy
10,398
+725
+7% +$28.5K 0.04% 133
2022
Q3 		$401K Buy
9,673
+894
+10% +$45.9K 0.04% 184
2022
Q2 		$524K Buy
8,779
+4,678
+114% +$288K 0.05% 136
2022
Q1 		$298K Buy
+4,101
New +$285K 0.01% 199

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

E Fund Management's RARE Position: Q2 2026 in Review

E Fund Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 31% in Q2 2026, selling an estimated $161K and leaving 14,334 shares worth $479K. The position accounts for 0.01% of the portfolio, ranked #278.

E Fund Management first reported a position in RARE in Q1 2022 and has held it in 16 quarters since. The position peaked at $568K in Q4 2023. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • E Fund Management held 14,334 shares of Ultragenyx Pharmaceutical worth $479K as of Q2 2026.
  • E Fund Management sold 6,462 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $161K.
  • Ultragenyx Pharmaceutical made up 0.01% of E Fund Management's portfolio in Q2 2026, its #278 holding.
  • E Fund Management first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Ultragenyx Pharmaceutical position peaked at $568K in Q4 2023.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.